The Outcome and Safety of Re-challenge Lutetium-177 PSMA ( 177 Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer —a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
We report the use of low-dose Taxol-based chemotherapy (modified dose 25 mg/m2 weekly × 6 weeks) as a radiosensitizer with re-challenge177Lu-PSMA therapy (4 cycles). In a period of 3 years, the patient underwent a total of 8 cycles of177Lu-PSMA with a cumulative dose of 51.8 GBq. All therapies were uneventful and well tolerated. There was a good response to re-challenge177Lu-PSMA therapy and low-dose docetaxel (Taxol-177Lu-PSMA) with no recorded tumour resistance.
Source: Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Nuclear Medicine | Prostate Cancer | Taxotere